Results 111 to 120 of about 12,722 (192)

ANMCO/ELAS/SIBioC Consensus Document: Biomarkers in heart failure [PDF]

open access: yes, 2017
Biomarkers have dramatically impacted the way heart failure (HF) patients are evaluated and managed. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or ...
Aimo, Alberto   +15 more
core   +1 more source

Vascular Endothelial Effects of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction: Randomized Controlled Trial [PDF]

open access: yes
BACKGROUND The mechanism of how sacubitril/valsartan improves outcomes in heart failure with reduced ejection fraction (HFrEF) is still incompletely understood.
Barthelmes, Jens   +9 more
core   +1 more source

Effect of sacubitril/valsartan on lipid metabolism in patients with chronic kidney disease combined with chronic heart failure: a retrospective study

open access: yesLipids in Health and Disease
Background and objective Dyslipidemia is significantly more common in those with concurrent chronic kidney disease (CKD) and chronic heart failure (CHF).
Manzhi Li   +6 more
doaj   +1 more source

Induction of ischaemic cardiomyopathy in mice without off‐target effects

open access: yes
Experimental Physiology, EarlyView.
Mark T. Waddingham, James T. Pearson
wiley   +1 more source

Comparison of the effect of Sacubitril /Valsartan with Losartan and Captopril in improving right ventricular function in patients with right heart failure, a randomized clinical controlled trial [PDF]

open access: yes
Background: There is evidence supporting the efficacy of Sacubitril /Valsartan for improving left heart failure, but few studies have examined its effects on right ventricular (RV) dysfunction.
Hajahmadi, Marjan   +3 more
core   +2 more sources

Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)

open access: yesThe Journal of Clinical Hypertension
Sacubitril/valsartan, an angiotensin receptor‐neprilysin inhibitor, has demonstrated a superior blood pressure‐lowering effect compared with renin‐angiotensin system inhibitors in several clinical trials.
Koichi Yamamoto   +8 more
doaj   +1 more source

DEVELOPMENT OF ASSAY METHOD AND FORCED DEGRADATION STUDY OF VALSARTAN AND SACUBITRIL BY RP-HPLC IN TABLET FORMULATION [PDF]

open access: yes, 2016
Objective: A stability-indicating high performance liquid chromatographic (HPLC) method was developed and validated for the estimation of combined tablet formulation of valsartan and sacubitril.Methods: Chromatographic separation was optimized by ...
Naazneen, S., Sridevi, A.
core   +1 more source

Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction

open access: yesFrontiers in Pharmacology
Background and aim:Heart failure with preserved ejection fraction (HFpEF) is associated with an increased risk of heart failure (HF) hospitalizations and cardiovascular death (CVD).
Ronen Arbel   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy